Literature DB >> 8638000

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.

P D Shreve1, H B Grossman, M D Gross, R L Wahl.   

Abstract

PURPOSE: To evaluate the accuracy of positron emission tomography (PET) with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (FDG) in the detection of osseous and soft-tissue metastases of prostate cancer.
MATERIALS AND METHODS: Thirty-four patients (mean age, 71 years) with biopsy-proved prostate cancer and known or suspected metastatic disease were examined. Blinded interpretation of the PET images was compared with bone scan, CT, and clinical follow-up findings.
RESULTS: In 202 untreated osseous metastases in 22 patients, the sensitivity of FDG PET was 65% (131 of 202 metastases), with a positive predictive value of 98% (131 of 133 positive findings). The estimated standardized uptake value in metastases was 2.1-5.7. Soft-tissue metastases to the lymph nodes or liver were identified, but evaluation of pelvic lymph node metastases was severely limited because of bladder tracer activity.
CONCLUSION: FDG PET can help identify osseous and soft-tissue metastases of prostate cancer with a high positive predictive value but is less sensitive than bone scintigraphy in the identification of osseous metastases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8638000     DOI: 10.1148/radiology.199.3.8638000

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  73 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Imaging features of primary and secondary malignant tumours of the sacrum.

Authors:  E Thornton; K M Krajewski; K N O'Regan; A A Giardino; J P Jagannathan; N Ramaiya
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

3.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

4.  Osteoblastic bone metastases in breast cancer: is not seeing believing?

Authors:  Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11       Impact factor: 9.236

5.  FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy.

Authors:  Ora Israel; Anat Goldberg; Alicia Nachtigal; Daniela Militianu; Rachel Bar-Shalom; Zohar Keidar; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-22       Impact factor: 9.236

6.  Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.

Authors:  Gustavo S P Meirelles; Heiko Schöder; Gregory C Ravizzini; Mithat Gönen; Josef J Fox; John Humm; Michael J Morris; Howard I Scher; Steven M Larson
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

Review 7.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 8.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

9.  Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT.

Authors:  Wellington K Hsu; Mandeep S Virk; Brian T Feeley; David B Stout; Arion F Chatziioannou; Jay R Lieberman
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

10.  The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.

Authors:  Joo-Won Min; Sang-Won Um; Jae-Jun Yim; Chul-Gyu Yoo; Sung Koo Han; Young-Soo Shim; Young Whan Kim
Journal:  J Korean Med Sci       Date:  2009-04-21       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.